Abstract
Rare-disease-focused Neurogene has debuted with $68.5 million in its first formal round of financing from investors that include Samsara BioCapital, EcoR1 Capital, and Redmile Group. The biotech firm is developing gene therapies for rare neurological diseases and plans to use the proceeds to fund clinical studies, invest in technology, and build a viral vector production site. Neurogene, which partners with academic scientists and patient advocacy groups, is initially pursuing gene therapies for two lysosomal storage disorders and a rare form of the sensory disorder Charcot-Marie-Tooth.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
